News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Capital return
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock. By their very nature, these stocks carry above-average risk and volatility. …
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Halozyme Therapeutics (HALO) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might …
The Top 5 Analyst Questions From Halozyme Therapeutics's Q2 Earnings Call Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management's attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen …
Wedge Capital Management L L P NC has invested $31.61 million in Halozyme Therapeutics, Inc., acquiring 403,824 shares. Halozyme Therapeutics, a biopharmaceutical company, reported strong quarterly results with EPS of $2.28 and revenue of $481 million, exceeding analyst expectations. The company maintains a "Moderate …
Handelsbanken Fonder AB significantly increased its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 28.1% in Q2 2026, now holding 631,899 shares valued at $49.5 million. This move is part of broader institutional investment, with various firms adjusting their holdings, and insiders also making transactions. …
Halozyme Therapeutics director Bernadette Connaughton sold 1,626 shares of company stock for a total of $167,152 on August 10, 2026, at a price of $102.8 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025. Following the …
Halozyme Therapeutics (HALO) director Bernadette Connaughton sold 1,626 shares of common stock at $102.80 per share on August 10, 2026, under a Rule 10b5-1 trading plan adopted in May 2025. Following this transaction, she directly holds 40,418 shares. The sale, valued at approximately $167,000, …
Halozyme Therapeutics (HALO) filed a Form 144, indicating an affiliate's intention to sell common stock through Morgan Stanley Smith Barney LLC. These planned sales are linked to stock option exercises set for August 11, 2026, involving transactions for 32,659, 5,277, and 3,766 shares of …
Zymeworks Inc., a biotechnology company, has announced its participation in several upcoming investor conferences in September 2026. Management will attend the Wells Fargo Healthcare Conference, Citi’s Biopharma Back to School Summit, Morgan Stanley Healthcare Conference, and H.C. Wainwright Annual Global Investment Conference, engaging in …
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q2 CY2026, with sales up 47.7% year on year to $481 million. The company's full-year revenue guidance of $1.87 billion at …
Halozyme Therapeutics (NASDAQ:HALO) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $91.20, though some targets have been raised to $115. The company exceeded quarterly expectations with $2.28 EPS and $481 million in revenue, leading to positive …
Halozyme Therapeutics (HALO) recently reported strong Q2 earnings, with revenue of US$481 million and net income of US$229.91 million, leading to raised full-year revenue guidance and new collaboration agreements. Despite a significant 1-year share price return of 63.17%, the company faces mixed valuation signals, …
Halozyme Therapeutics insider Bernadette Connaughton plans to sell 1,626 shares of common stock, valued at $167,673.12, through Morgan Stanley Smith Barney LLC on August 10, 2026. These shares originated from Restricted Stock Units granted in April 2025. The filing also details prior sales under …
[Wall Street sign in Lower Manhattan, NYC] georgeclerk * Zymeworks (ZYME [https://seekingalpha.com/symbol/ZYME]) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. * The bank sees shares rising due to an August 25 FDA action date for …
Gradient Investments LLC has purchased a new stake in Halozyme Therapeutics, Inc. ($HALO), acquiring 16,437 shares valued at approximately $1.29 million. This investment comes as Halozyme reported a strong second quarter with significant revenue growth and raised its 2026 guidance, attracting positive analyst sentiment. …
Halozyme Therapeutics, Inc. reported a strong quarter, exceeding analysts' earnings expectations. Following these results, analysts have updated their financial forecasts for the current year, indicating a positive outlook for the company's performance. This update reflects increased confidence in Halozyme's financial trajectory.
Halozyme Therapeutics reported record second-quarter results with revenue up to US$481 million and net income of US$229.91 million, leading to increased full-year 2026 revenue guidance. The company also accelerated share buybacks and secured new ENHANZE collaborations, reinforcing its royalty-led business model. While these achievements …
Halozyme Therapeutics (HALO) has seen a 106.2% return over five years, but its current valuation suggests the stock is expensive, trading at 29.2x earnings compared to a fair P/E of 20.1x. Despite strong financial results and collaboration agreements, the company's P/E ratio is above …
Halozyme Therapeutics reported record second-quarter results with revenue at US$481 million and net income at US$229.91 million, leading to a 24.9% stock increase. The company raised its 2026 revenue guidance to US$1.84 billion - US$1.91 billion and boosted share buybacks by an additional US$175.01 …
Analysts have raised the average 12-month price target for Halozyme Therapeutics, Inc. (HALO) stock to $99.56, up from $86.89. This new target suggests a potential upside of approximately 16% from its recent closing price. The consensus rating among 11 analysts remains a "Buy," with …
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Halozyme earnings beat and guidance hike reshape the story Halozyme Therapeutics (HALO) just put fresh numbers on the table, reporting second quarter 2026 results, raising …
Halozyme Therapeutics (HALO) stock rallied 20% after reporting strong Q2 2026 earnings, exceeding revenue and EPS expectations, driven by a 47.5% increase in total revenue and 39.2% increase in net income. The company also raised its full-year 2026 revenue and earnings guidance, reinforcing its …
Search by ticker symbol or company name and select a result to open its chart.